Article Text

Download PDFPDF
Ovarian Cancer: The Role of Functional Imaging as an End Point in Clinical Trials
  1. Evis Sala, MD, PhD*,
  2. Nandita DeSouza, MD,
  3. Susanna I. Lee, MD,
  4. Mostafa Atri, MD§ and
  5. Hedvig Hricak, MD, PhD
  1. * Department of Radiology, Addenbrookes Hospital, Cambridge;
  2. Institute of Cancer Research and Royal Marsden Hospital, Surrey, United Kingdom;
  3. Massachusetts General Hospital, Harvard Medical School, Boston, MA;
  4. § Abdominal Division, Medical Imaging, University of Toronto, Ontario, Canada; and
  5. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY.
  1. Address correspondence and reprint requests to Evis Sala, MD, PhD, Department of Radiology, Box 218, Addenbrookes Hospital, Hills Rd, Cambridge, CB2 0QQ United Kingdom. E-mail: es220{at}


The Gynaecological Cancer InterGroup conducts collaborative trials in gynecologic cancer and also aims to develop standards that can be used to strengthen all aspects of study methodology. There is an urgent need to develop more refined imaging end points that can be used as early treatment response biomarkers in ovarian cancer. Therefore, the Gynaecological Cancer InterGroup commissioned an expert position paper on the role of functional imaging as an end point in clinical trials in ovarian cancer. In this position paper, we state the limitation of current anatomical imaging methods used in clinical trials, highlight the potential of functional imaging, and provide key recommendations on the use of functional imaging as an end point in ovarian cancer clinical trials.

  • Ovarian cancer
  • Functional imaging
  • Biomarker
  • Clinical trial

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors have no disclosures.